# Clinical trials recruiting in Serbia: 222 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 222 trials recruiting or not yet recruiting with a site in Serbia, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Serbia: 222 rows for $11.10, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/country/serbia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 222
- Recruiting or not yet: 222
- Read on: November 19, 2026

## Trials

The 25 newest of 222, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07931599 | A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 1,060 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931599) |
| November 10, 2026 | NCT07927751 | Holistic Empowerment Assistance Recovery Transformation | Institute for Cardiovascular Diseases Dedinje | Not applicable | Recruiting | Rehabilitation Programs, Rehabilitation After Cardiovascular Surgery, Cardiovascular Care | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927751) |
| October 21, 2026 | NCT07885891 | Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia | Wockhardt | Phase 3 | Not yet recruiting | Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP) | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885891) |
| October 14, 2026 | NCT07874139 | Prospective Study on Antimicrobial RESIstance in Chronic Pulmonary DiseasE | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Observational | Recruiting | Chronic Lung Diseases | 683 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874139) |
| September 29, 2026 | NCT07845487 | A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845487) |
| August 27, 2026 | NCT07789015 | A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Idiopathic Inflammatory Myopathies | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789015) |
| August 24, 2026 | NCT07783399 | The Effects of Carnitine Supplementation on Oocytes in Women Undergoing IVF Process | The Obstetrics and Gynaecology Clinic Narodni Front | Not applicable | Recruiting | Infertility (IVF Patients) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783399) |
| August 10, 2026 | NCT07753993 | A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. | AstraZeneca | Phase 3 | Recruiting | Chronic Kidney Disease | 7,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753993) |
| August 4, 2026 | NCT07745504 | A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | Novo Nordisk A/S | Phase 3 | Recruiting | Overweight, Obesity | 285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745504) |
| August 4, 2026 | NCT07743918 | Vitamin D Status and Clinical Outcomes in Locally Advanced Cervical Cancer | University of Kragujevac | Observational | Recruiting | Locally Advanced Cervical Cancer, Vitamin D Concentration | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743918) |
| July 13, 2026 | NCT07698951 | Evaluating Percutaneous Repair Of The Atrial Septum With A Novel PFO Occluder: The PROTEA-PFO OUS Study | Recross Cardio, Inc. | Not applicable | Recruiting | PFO, PFO - Patent Foramen Ovale, Cryptogenic Stroke, Patent Foramen Ovale, PFO-associated Stroke | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698951) |
| July 9, 2026 | NCT07691970 | Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From... | AstraZeneca | Phase 3 | Recruiting | Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus | 1,072 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691970) |
| July 6, 2026 | NCT07683325 | NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's... | Agomab Spain S.L.U. | Phase 2 | Recruiting | Fibrostenotic Crohn's Disease | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683325) |
| June 30, 2026 | NCT07677059 | A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study | Kymera Therapeutics, Inc. | Phase 2 | Recruiting | Asthma (Diagnosis) | 264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07677059) |
| June 26, 2026 | NCT07671963 | Bone Substitutes and NIPSA in Intrabony Periodontal Defects: A Randomized Controlled Trial | University of Belgrade | Not applicable | Recruiting | Periodontitis (Stage 3), Minimally Invasive Surgical Procedures, Bone Substitutes | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671963) |
| June 17, 2026 | NCT07655388 | Wound Healing, Dressing Type, and Dressing Change Frequency in THA | Clinical Center of Vojvodina | Not applicable | Recruiting | Wound Healing Time, Total Hip Arthroplasty (THA) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07655388) |
| June 8, 2026 | NCT07633288 | A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With... | SynAct Pharma Aps | Phase 2 | Recruiting | Respiratory Viral Infection | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07633288) |
| June 5, 2026 | NCT07630714 | A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to \< 18 Years... | AstraZeneca | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630714) |
| June 4, 2026 | NCT07625644 | BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) | SystImmune Inc. | Phase 3 | Recruiting | Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung... | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625644) |
| June 1, 2026 | NCT07618130 | Opioid-Free Anesthesia and Pain Study in Cardiac Surgery Patients | Clinical Centre of Serbia | Not applicable | Not yet recruiting | Posoperativ Pain, Chronich Pain, Postoperativ Delirum, Opoid-free Managment | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07618130) |
| May 8, 2026 | NCT07576686 | AI-Guided CBT for Depression and Anxiety | Sponsor not shown (see the record) | Not applicable | Recruiting | Depression - Major Depressive Disorder, Anxiety Disorders | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576686) |
| April 30, 2026 | NCT07559903 | ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety) | Emory University | Observational | Recruiting | Coronary Artery Disease | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559903) |
| April 14, 2026 | NCT07527741 | A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment... | Hoffmann-La Roche | Observational | Recruiting | Early-stage HER2+ Breast Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527741) |
| April 13, 2026 | NCT07525375 | A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in... | AstraZeneca | Phase 2 | Recruiting | Asthma | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07525375) |
| March 31, 2026 | NCT07503873 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative... | TG Therapeutics, Inc. | Phase 2 | Recruiting | Multiple Sclerosis | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503873) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| University Clinical Center Kragujevac | Kragujevac | 25 |
| University Clinical Center of Serbia | Belgrade | 20 |
| University Clinical Center Nis | Niš | 12 |
| Clinical Center of Serbia | Belgrade | 8 |
| Military Medical Academy | Belgrade | 8 |
| Clinical Hospital Center Bezanijska Kosa | Belgrade | 8 |
| University Clinical Centre of Serbia | Belgrade | 7 |
| Institute of Mental Health Serbia | Belgrade | 7 |
| University Clinical Center NIS | Niš | 7 |
| Dedinje Cardiovascular Institute | Dedinje | 7 |
| University Clinical Center of Kragujevac | Kragujevac | 5 |
| Special Hospital for Psychiatric Diseases Kovin | Kovin | 5 |
| Clinical Center of Vojvodina | Novi Sad | 5 |
| University Clinical Centre of Kragujevac | Kragujevac | 5 |
| General Hospital Pancevo | Pančevo | 4 |
| Clinical Hospital Center Zemun | Belgrade | 4 |
| Clinic of Neurology and Psychiatry for Children and Youth | Belgrade | 4 |
| General Hospital "Djordje Joanovic" | Zrenjanin | 4 |
| Clinical Center Kragujevac | Kragujevac | 4 |
| Institute for Treatment and Rehabilitation, Niska Banja | Niška Banja | 3 |
| Clinical Hospital Center Bezanijska kosa | Belgrade | 3 |
| Center for Health Sciences | Belgrade | 3 |
| Clinical Hospital Center Dragisa Misovic Dedinje | Belgrade | 3 |
| Institute of Mental Health | Belgrade | 3 |
| Institute of Rheumatology | Belgrade | 3 |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 1/2 | 6 |
| Phase 2 | 42 |
| Phase 2/3 | 10 |
| Phase 3 | 83 |
| Phase 4 | 3 |
| Not applicable | 38 |
| Observational | 33 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Colitis, Ulcerative | 10 |
| Heart Failure | 8 |
| Coronary Artery Disease | 7 |
| Crohn Disease | 7 |
| Schizophrenia | 5 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Hypertension | 4 |
| Asthma | 4 |
| Breast Neoplasms | 4 |
| Purpura, Thrombocytopenic, Idiopathic | 4 |
| Lupus Erythematosus, Systemic | 4 |
| Atrial Fibrillation | 4 |
| Heart Diseases | 4 |
| Depressive Disorder, Major | 4 |
| Psychotic Disorders | 4 |
| Myasthenia Gravis | 4 |
| Cardiovascular Diseases | 3 |
| Inflammatory Bowel Diseases | 3 |
| Autoimmune Diseases | 3 |
| Overweight | 3 |
| Obesity | 3 |
| Ischemic Stroke | 3 |
| Recurrence | 3 |
| Carcinoma, Hepatocellular | 3 |
| Liver Neoplasms | 3 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| University of Belgrade | 10 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 8 |
| [Intra-Cellular Therapies, Inc.](https://specstream.ai/data/clinical-trials/company/intra-cellular-therapies-inc) | 8 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 8 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 6 |
| [Octapharma](https://specstream.ai/data/clinical-trials/company/octapharma) | 5 |
| [Neurocrine Biosciences](https://specstream.ai/data/clinical-trials/company/neurocrine-biosciences) | 5 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 5 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 3 |
| Center for Health Sciences, Serbia | 3 |
| [Karuna Therapeutics, Inc., a Bristol Myers Squibb company](https://specstream.ai/data/clinical-trials/company/karuna-therapeutics-inc-a-bristol-myers-squibb-company) | 3 |
| [ACADIA Pharmaceuticals Inc.](https://specstream.ai/data/clinical-trials/company/acadia-pharmaceuticals-inc) | 3 |
| Institute for Cardiovascular Diseases Dedinje | 3 |
| [Genzyme, a Sanofi Company](https://specstream.ai/data/clinical-trials/company/genzyme-a-sanofi-company) | 3 |
| [H. Lundbeck A/S](https://specstream.ai/data/clinical-trials/company/h-lundbeck-a-s) | 3 |
| [argenx](https://specstream.ai/data/clinical-trials/company/argenx) | 3 |
| Weill Medical College of Cornell University | 3 |
| [Italfarmaco](https://specstream.ai/data/clinical-trials/company/italfarmaco) | 3 |
| Clinical Centre of Serbia | 2 |
| Berlin Heals GmbH | 2 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 2 |
| Kiniksa Pharmaceuticals International, plc | 2 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 2 |
| Kymera Therapeutics, Inc. | 2 |
| Institute of Cardiovascular Diseases, Vojvodina | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Avionics shops in the United States](https://specstream.ai/data/businesses/avionics-shops/united-states)
- [Food and beverage consultants in the United States](https://specstream.ai/data/businesses/food-and-beverage-consultants/united-states)
- [Polish restaurants in the United States](https://specstream.ai/data/businesses/polish-restaurants/united-states)
- [Automotive companies in the United States](https://specstream.ai/data/businesses/automotive-companies/united-states)
- [Fmcg wholesalers in the United States](https://specstream.ai/data/businesses/fmcg-wholesalers/united-states)
- [Podiatrists in the United States](https://specstream.ai/data/businesses/podiatrists/united-states)
